EU Parliament sets 90 days for pricing generics

The European Parliament adopted a proposed Transparency Directive that will require member states to make pricing and reimbursement decisions on generic and biosimilar products within 90 days of approval. The timeline is longer than the 60 days that was included in a proposed directive that was approved in December by the Parliament's Environment and Public Health Committee, and the 30 days the European Commission had originally proposed last March (see BioCentury Extra, Dec. 18, 2012).

Previously, member states had 180 days to issue pricing and reimbursement decisions for both generics and innovative drugs. Under the adopted directive, member states still have 180 days to issue decisions for innovative drugs. ...